Evaluating Myriad Genetics: Insights From 4 Financial Analysts
Portfolio Pulse from Benzinga Insights
Four financial analysts have provided diverse ratings for Myriad Genetics (NASDAQ:MYGN) over the last three months, with a shift towards a more positive outlook in the last 30 days. The average 12-month price target for MYGN has increased by 17.65% to $20.00, with a high estimate of $23.00 and a low of $14.00. Myriad Genetics is a molecular diagnostics company with recent positive revenue growth but faces challenges with net margin, ROE, ROA, and debt management.
December 21, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have mixed opinions on MYGN, but the average price target has increased, indicating a positive sentiment shift. The company has shown revenue growth but struggles with profitability and debt management.
The increase in the average price target suggests a positive outlook, which could lead to short-term price appreciation. However, the company's financial challenges may temper gains.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100